Prospective evaluation of 2-[18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma

Journal of Clinical Oncology

Volumn 16, Issue 5, 1998, Pages 1770-1776

  Macfarlane, David J ^a   Sondak, Vernon ^a   Johnson, Timothy ^a   Wahl, Richard L ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FEMALE; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MALE; MELANOMA; METASTASIS; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

EID: 0031860806     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.5.1770     Document Type: Article

References (28)

1. Ross MI, Balch CM: The current management of cutaneous melanoma. Adv Surg 24: 139-200, 1991
2. Evans GRD, Manson PN: Review and current perspectives of cutaneous malignant melanoma. J Am Coll Surg 178:523-540, 1994
3. Brossart P, Keilholz U, Willhauck M, et al: Hematogenous spread of malignant melanoma cells in different stages of disease. J Invest Dermatol 101:887-889, 1993
4. Vollmer RT: Malignant melanoma. A multivariate analysis of prognostic factors. Pathol Annu 24:383-407, 1989
5. Balch CM: The role of elective lymph node dissection in melanoma: Rationale, results and controversies. J Clin Oncol 6:163-172, 1988
6. Cochran AJ, Wen DR, Morton DL: Management of the regional lymph nodes in patients with cutaneous malignant melanoma. World J Surg 16:214-221, 1992
7. McCarthy WH, Shaw HM, Cascinelli N, et al: Elective lymph node dissection for melanoma: Two perspectives. World J Surg 16:203-213, 1992
8. Kroon BB, Jonk A: Elective lymph node dissection in melanoma: Still a controversial issue. Neth J Surg 43:129-132, 1991
9. Karakousis CP, Hena MA, Emrich LJ, et al: Axillary node dissection in malignant melanoma: Results and complications. Surgery 108:10-17, 1990
10. Gumport SL, Harris MN: Results of regional lymph node dissection for melanoma. Ann Surg 179:105-108, 1974
11. Slingluff CL Jr, Stidham KR, Ricci WM, et al: Surgical management of regional lymph nodes in patients with melanoma. Experience with 4682 patients. Ann Surg 219:120-130, 1994
12. Lyons JH III, Cockerell CJ: Elective lymph node dissection for melanoma. J Am Acad Dermatol 30:467-480, 1994
13. Yao WJ, Hoh CK, Glaspy F, et al: Whole body FDG-PET imaging for staging of malignant melanoma: Is it cost effective? J Nucl Med 35:8P, 1994 (abstr 20)
14. 18F]-2-deoxy-D-glucose in the imaging of malignant melanoma. J Nucl Med 34:1429-1437, 1993
15. Dahibom M, Hoffman EJ, Hoh CK, et al: Whole-body positron emission tomography: Part I. Methods and performance characteristics. J Nucl Med 33:1191-1199, 1992
16. 18F]-2-deoxy-D-glucose: Variations with body weight and a method for correction. Radiology 189:847-850, 1993
17. Woodward HQ, Gigler RE, Freed B, et al: Expression of tissue isotope distribution. J Nucl Med 16:958-959, 1975
18. Strauss LG, Dimitrakopoulou-Strauss A, van Kaick G: PET studies with F-18-deoxyglucose (FDG) in patients with metastatic melanoma prior and after therapy. J Nucl Med 35:38P, 1994 (abstr 142)
19. 18F]fluoro-D-glucose (FDG) for the detection of tumor involvement in lymph nodes. J Nucl Med 31:1831-1835, 1990
20. Wahl RL, Cody RL, Hutchins GD, et al: Primary and metastatic breast carcinoma: initial and clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 179:765-770, 1991
21. Adler LP, Crowe JP, Al-Kaisi NK, et al: Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. Radiology 187:743-750, 1993
22. Braams JW, Pruim J, Freling NJM, et al: Detection of lymph node metastases of squamous-cell cancer of the head and neck with FDG-PET and MRI. J Nucl Med 36:211-216, 1995
23. Jabour BA, Choi Y, Rege SD, et al: Extracranial head and neck: PET imaging with 2-[F-18]fluoro-2-deoxy-D-glucose and MR imaging correlation. Radiology 186:27-35, 1993
24. Liewendahl K, Pyrönen S: Radioimmunodetection and radioimmunotherapy of malignant melanoma. Acta Oncol 32:717-721, 1993
25. Wahl RL, Liebert M, Headington J, et al: Lymphoscintigraphy in melanoma: Initial evaluation of a low protein dose monoclonal antibody cocktail. Cancer Res 50:941s-948s, 1990 (suppl)
26. Maffioli L, Mascheroni L, Mongioj V, et al: Scintigraphic detection of melanoma metastases with a radiolabeled benzamide ([iodine-123]-(S)-IBZM). J Nucl Med 35:1741-1747, 1994
27. Morton DL, Wen D, Foshag LJ, et al: Intraoperative lymphatic mapping and selective cervical lymphadenectomy for early-stage melanomas of the head and neck. J Clin Oncol 11:1751-1756, 1993
28. Bhatththiry M, Glass E, Kirgan D, et al: Efficacy of FDG whole body PET in staging and clinical management of metastatic malignant melanoma. J Nucl Med 35:230P, 1994 (abstr 940)